Robert Alan Pearlstein

Dr. Robert Alan Pearlstein


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2010 in Proteins: Structure, Function, and Bioinformatics
Verified
Journal Article
Closed access
PDF file
RPRobert Alan Pearlstein
Robert Alan Pearlstein
QHQi‐Ying Hu
Qi‐Ying Hu
JZJing Zhou
Jing Zhou
DYDavid Yowe
David Yowe
JLJulian Levell
Julian Levell
RARobert Abel
Robert Abel

6 March 2013 in Proteins: Structure, Function, and Bioinformatics
Verified
Journal Article
Closed access
PDF file
RPRobert Alan Pearlstein
Robert Alan Pearlstein
WSWoody Sherman
Woody Sherman
RARobert Abel
Robert Abel

1 February 2017 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
RPRobert Alan Pearlstein
Robert Alan Pearlstein
CDCallum J. Dickson
Callum J. Dickson
VHViktor Hornak
Viktor Hornak

29 April 2016 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
RPRobert Alan Pearlstein
Robert Alan Pearlstein
KMK. Andrew MacCannell
K. Andrew MacCannell
GEGül Erdemli
Gül Erdemli
SYSarita Yeola
Sarita Yeola
GHGabriel Helmlinger
Gabriel Helmlinger
JDJosé S. Duca
José S. Duca
Blockade of the hERG potassium channel prolongs the ventricular action potential (AP) and QT interval, and triggers early after depolarizations (EADs) and torsade de pointes (TdP) arrhythmia. Opinions differ as to the causal relationship between hERG blockade and TdP, the relative weighting of other contributing factors, definitive metrics of preclinical proarrhythmicity, and the true safety margin in humans. Here, we have used in silico techniques to characterize the effects of channel gating and binding kinetics on hERG occupancy, and of blockade on the human ventricular AP. Gating effects differ for compounds that are sterically compatible with closed channels (becoming trapped in deactivated channels) versus those that are incompatible with the closed/closing state, and expelled during deactivation. Occupancies of trappable blockers build to equilibrium levels, whereas those of non-trappable blockers build and decay during each AP cycle. Occupancies of ~83% (non-trappable) versus ~63% (trappable) of open/inactive channels caused EADs in our AP simulations. Overall, we conclude that hERG occupancy at therapeutic exposure levels may be tolerated for non-trappable, but not trappable blockers capable of building to the proarrhythmic occupancy level. Furthermore, the widely used Redfern safety index may be biased toward trappable blockers, overestimating the exposure-IC₅₀ separation in non-trappable cases.

4 November 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HWHongbin Wan
Hongbin Wan
GSGianluca Selvaggio
Gianluca Selvaggio
RPRobert Alan Pearlstein
Robert Alan Pearlstein
The human ether-a-go-go-related voltage-gated cardiac ion channel (commonly known as hERG) conducts the rapid outward repolarizing potassium current in cardiomyocytes (IKr). Inadvertent blockade of this channel by drug-like molecules represents a key challenge in pharmaceutical R&D due to frequent overlap between the structure-activity relationships of hERG and many primary targets. Building on our previous work, together with recent cryo-EM structures of hERG, we set about to better understand the energetic and structural basis of promiscuous blocker-hERG binding in the context of Biodynamics theory. We propose a two-step blocker binding process consisting of: Lastly, we highlight possible flaws in the current hERG safety index (SI), and propose an alternate in vivo-relevant strategy factoring in:

6 November 2020 in ACS Pharmacology & Translational Science
Verified
Journal Article
Closed access
HWHongbin Wan
Hongbin Wan
VAVibhas Aravamuthan
Vibhas Aravamuthan
RPRobert Alan Pearlstein
Robert Alan Pearlstein